Patents by Inventor Susan Babuka

Susan Babuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8388942
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-?, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.
    Type: Grant
    Filed: April 29, 2008
    Date of Patent: March 5, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Sidney N Wolfe, Bret A Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Patent number: 8333958
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: December 18, 2012
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20110104116
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Application
    Filed: January 11, 2011
    Publication date: May 5, 2011
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Patent number: 7892531
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: February 22, 2011
    Assignee: Novartis Vaccines and Diagnostics
    Inventors: Bret A Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Patent number: 7544354
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-?, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: June 9, 2009
    Assignee: Novartis Vaccines and Diagnostics
    Inventors: Sidney N. Wolfe, Bret A. Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Publication number: 20090123424
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-?) and compositions comprising substantially monomeric IFN-? are provided. In one purification method, substantially purified IFN-? or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-? residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-?.
    Type: Application
    Filed: April 29, 2008
    Publication date: May 14, 2009
    Inventors: Sidney N. Wolfe, Bret A. Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Publication number: 20080193415
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Application
    Filed: April 9, 2008
    Publication date: August 14, 2008
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Patent number: 7399463
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: July 15, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Patent number: 7371373
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: May 13, 2008
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20050142110
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Application
    Filed: February 18, 2005
    Publication date: June 30, 2005
    Applicant: Chiron Corporation
    Inventors: Bret Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Patent number: 6887462
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-?) and methods useful in their preparation are provided. The compositions comprise the IFN-? solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-? in pharmaceutical compositions, are provided.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: May 3, 2005
    Assignee: Chiron Corporation
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20040191219
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-&bgr;) and methods useful in their preparation are provided. The compositions comprise the IFN-&bgr; solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-&bgr; in pharmaceutical compositions, are provided.
    Type: Application
    Filed: April 9, 2004
    Publication date: September 30, 2004
    Applicant: Chiron Corporation
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20040115169
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-&bgr;) and compositions comprising substantially monomeric IFN-&bgr; are provided. In one purification method, substantially purified IFN-&bgr; or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-&bgr;, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-&bgr;.
    Type: Application
    Filed: December 31, 2003
    Publication date: June 17, 2004
    Applicant: Chiron Corporation
    Inventors: Sidney N. Wolfe, Bret A. Shirley, Susan Babuka, Dennis Fordham, Irina Esikova
  • Publication number: 20020172661
    Abstract: Stabilized pharmaceutical compositions comprising substantially monomeric interferon-beta (IFN-&bgr;) and methods useful in their preparation are provided. The compositions comprise the IFN-&bgr; solubilized in a low-ionic-strength formulation that maintains the composition at a pH of about 3.0 to about 5.0. Methods for preparing these compositions, and for increasing solubility of IFN-&bgr; in pharmaceutical compositions, are provided.
    Type: Application
    Filed: October 25, 2001
    Publication date: November 21, 2002
    Applicant: Chiron Corporation
    Inventors: Bret A. Shirley, Susan Babuka, Bao-Lu Chen, Maninder Hora, Minna Choe, Melanie Tellers
  • Publication number: 20020137895
    Abstract: Improved methods for purification and recovery of interferon-beta (IFN-&bgr;) and compositions comprising substantially monomeric IFN-&bgr; are provided. In one purification method, substantially purified IFN-&bgr; or variant thereof is precipitated and then dissolved in a guanidine hydrochloride (HCl) solution. Renaturation of the protein occurs by dilution with a suitable buffer. A similar purification method absent the precipitation step is also provided. Following renaturation of the IFN-&bgr;, residual guanidine HCl is removed by diafiltration or dialysis with a pharmaceutically acceptable buffer to prepare pharmaceutical compositions comprising substantially monomeric IFN-&bgr;.
    Type: Application
    Filed: October 25, 2001
    Publication date: September 26, 2002
    Applicant: Chiron Corporation
    Inventors: Sidney N. Wolfe, Bret A. Shirley, Susan Babuka, Dennis Fordham, Irina Esikova